OCA has been extensively investigated in NAFLD, and multiple beneficial metabolic effects were observed upon activation of FXR leading to reduction of hepatic bile acid concentrations (Figure 3). The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.